Modified Albumin-Bilirubin Grade After Curative Treatment: Predicting the Risk of Late Intrahepatic Recurrence of Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Modified Albumin-Bilirubin Grade After Curative Treatment: Predicting the Risk of Late Intrahepatic Recurrence of Hepatocellular Carcinoma

Published:2024 Issue: Volume:39 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Goh Myung Ji¹^ORCID,Park Hee Chul²^ORCID,Kim Nalee²^ORCID,Bae Bong Kyung³^ORCID,Choi Moon Seok¹^ORCID,Rhu Jinsoo⁴^ORCID,Lee Min Woo⁵^ORCID,Jeong Woo Kyoung⁵^ORCID,Kim Minji⁶^ORCID,Kim Kyunga⁶^ORCID,Yu Jeong Il²^ORCID

Affiliation:

1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

3. Department of Radiation Oncology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

4. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

5. Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

6. Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea.

Funder

National Research Foundation of Korea

Samsung Medical Center

Publisher

XMLink

Link

https://jkms.org/pdf/10.3346/jkms.2024.39.e251

Reference24 articles.

1. Prediction of Cancer Incidence and Mortality in Korea, 2023

2. Cancer statistics, 2023

3. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

4. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

5. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study